This application seeks five years of initial support to establish the Arizona Alzheimer's Disease Core Center (ADCC). The ADCC will provide the administrative structure, leadership, communication, support, and clinical and histopathological database needed to help fulfill our scientific mission, integrate our research program, promote our scientific progress, and ensure our accountability; it will work closely with researchers inside and outside Arizona, other ADC's, and the National Alzheimer's Coordinating Center (Core A). The ADCC will help researchers access data from and conduct studies in 400 patients with dementia, 80 patients with mild cognitive impairment (MCI), and 240 normal elderly control subjects who are clinically well characterized, followed annually, and enrolled in our brain donation program; it will annually evaluate 180 additional Hispanic subjects in these three groups and explore the feasibility of conducting studies in 6 Native American Nations and Tribes; and it will provide access to data acquired in an independent study of cognitively normal persons with no copies, one copy, and two copies of the apolipoprotein E4 allele (Core B). The ADCC will provide histopathological diagnoses in expired brain donors and high-quality brain tissue to researchers inside Arizona and around the world (Core C). It will increase the number of productive scientists involved in AD research through education, training, pilot studies, and collaborative research; it will enhance skills for the professional care of patients with AD and related disorders; it will educate the general public about AD and our ADCC; and it will provide innovative Hispanic and Native American educational outreach programs (Core D). The Arizona ADCC will further integrate, coordinate, and capitalize on resources and activities in our recently established, state-supported, multi-institutional Center for Alzheimer's Disease Research (CADR). The CADR's major theme is the early detection and prevention of AD. Its major goals: (1) to detect and track AD in patients with dementia and MCI, cognitively normal persons at genetic risk for AD, and laboratory animals using brain imaging techniques and other research methods; (2) to help clarify certain AD mechanisms and risk factors; (3) to further characterize the neural systems involved in aspects of memory, language, emotion, and consciousness, the cognitive operations to which they are related, and the extent to which they are preferentially affected by AD and aging; (4) to provide new methods and strategies for the study of AD and aging in persons and laboratory animals; (5) to help identify treatments to halt the progression and, indeed, prevent the onset of AD; and (6) to establish a truly integrated, scientifically productive """"""""research laboratory without walls,"""""""" which serves as a model of multi-disciplinary, multi-institutional research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
1P30AG019610-01
Application #
6353922
Study Section
Special Emphasis Panel (ZAG1-PCR-5 (M1))
Program Officer
Phelps, Creighton H
Project Start
2001-09-30
Project End
2006-06-30
Budget Start
2001-09-30
Budget End
2002-06-30
Support Year
1
Fiscal Year
2001
Total Cost
$933,641
Indirect Cost
Name
Sun Health Research Institute
Department
Type
DUNS #
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Subjective Cognitive Impairment and the Broad Autism Phenotype. Alzheimer Dis Assoc Disord 32:284-290
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Salloway, Stephen; Honigberg, Lee A; Cho, William et al. (2018) Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimers Res Ther 10:96
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Ortuño-Lizarán, Isabel; Esquiva, Gema; Beach, Thomas G et al. (2018) Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease. Acta Neuropathol Commun 6:90
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161

Showing the most recent 10 out of 794 publications